ExpreS2ion Biotechnologies is expected to release its Q1 2025 results on 15 May 2025. Later on the same day at 10:30, the management will present the results and the achievements in an online live presentation. The presentation will be followed by a Q&A session.

Dagens aktienyheder med Hafnia, MapsPeople og ExpreS2ion

ExpreS2ion has today announced that it will expand its ES2B-C001 study to include combination testing. This should increase the Clinical trial sites and patient population and could potentially increase commercial potential.

ExpreS2ion Biotech: Signs Letter of Intent with WuXi Vaccines to initiate technology evaluation of ExpreS2ion’s proprietary production platform ExpreS2™

Dagens aktienyheder med ExpreS2ion Biotechnologies og BioPorto A/S

Dagens aktienyheder med Gubra, Pharma Equity Group, Wirtek, ExpreS2ion Biotechnologies og Spar Nord Bank

ExpreS2ion has today informed the market about the progress on the HER2 breast cancer vaccine candidate, ES2B-C001, but also announced that they will no longer pursue the development of a CMV candidate, a collaboration with Evaxion Biotech.

Today, ExpreS2ion Biotechnologies’ CFO Keith Alexander presented the results and update on business for the fourth quarter of 2024. Furthermore, they gave some insight into the business case around the Breast cancer candidate currently commencing phase 1.

ExpreS2ion Biotechnologies is expected to release its Q4 2024 results on 6 February 2025. On the same day at 10:00, the company’s and CFO Keith Alexander will present the results and the achievements in an online live presentation. The management presentation will be followed by a Q&A session.